Recent advances in antiviral research: Identification of inhibitors of the herpesvirus proteases

Current Opinion in Chemical Biology

Volumn 1, Issue 2, 1997, Pages 190-196

  Flynn, Daniel L ^a   Abood, Norman A ^a   Holwerda, Barry C ^b  

^a PFIZER INC   (United States)

^b Dept of Infect Diseases Research ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPESVIRIDAE; HUMAN HERPESVIRUS 5;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR;

CHEMISTRY; ENZYMOLOGY; HERPES VIRUS INFECTION; HUMAN; REVIEW;

ANTI-HIV AGENTS; HERPESVIRIDAE INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS;

EID: 0031197207     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(97)80009-9     Document Type: Article

References (64)

1. Liu F, Roizman B: The herpes simplex virus 1 gene encoding a protease also contains within its coding domain the gene encoding the more abundant substrate. J Virol 1991, 65:5149-5156.
2. Welch AR, Woods AS, McNally LM, Cotter RJ, Gibson W: A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site. Proc Natl Acad Sci USA 1991, 88:10792-10796.
3. Gibson W, Hall MRT: Assemblin, an essential herpesvirus proteinase. Drug Des Discov 1997, 15:47-59. This paper, together with [1,2], provides the interested reader with an excellent background on the herpesvirus proteases.
4. Gao M, Matusick-Kumar L, Hurlburt W, DiTusa SF, Newcomb WW, Brown JC, McCann PJ III, Deckman I, Colonno RJ: The protease of herpes simplex virus type1 is essential for functional capsid formation and viral growth. J Virol 1994, 68:3702-3712.
5. Desai P, Watkins SC, Person S: The size and symmetry of B capsids of herpes simplex virus type 1 are determined by the gene-products of the UL26 open reading frame. J Virol 1994, 68:5365-5374.
6. Preston VG, Coates JAV, Rixon FJ: Identification and characterization of a herpes simplex virus gene product required for encapsidation of virus DNA. J Virol 1983, 45:1056-1064.
7. Hippenmeyer PJ, Rankin AM, Luckow VA, Neises GR: Protease deficient herpes simplex virus protects mice from lethal herpesvirus infection. J Virol 1997, 71:988-995. This is a critical reference highlighting the essential role of herpesvirus protease in viral replication.
8. Liu F, Roizman B: Differentiation of multiple domains in the herpes simplex virus 1 protease encoded by the UL26 gene. Proc Natl Acad Sci USA 1992, 89:2076-2080.
9. Welch AR, McNally LM, Gibson W: Cytomegalovirus assembly protein nested gene family: four 3′-coterminal transcripts encode four in-frame, overlapping proteins. J Virol 1991, 65:4091-4100.
10. Kennard J, Rixon FJ, Mcdougall IM, Tatman JD, Preston VG: The 25 amino acid residues at the carboxy terminus of the herpes simplex virus type-1 UL26.5 protein are required for the formation of the capsid shell around the scaffold. J Gen Virol 1995, 76:1611-1621.
11. Thomsen DR, Newcomb WW, Brown JC, Homa FL: Assembly of the herpes-simplex virus capsid: requirement for the carboxyl-terminal 25 amino acids of the proteins encoded by the UL26 and UL26.5 genes. J Virol 1995, 69:3690-3703.
12. Desai P, Person S: Molecular interactions between the HSV-1 capsid proteins as measured by the yeast two-hybrid system. Virology 1996, 220:516-521.
13. Wood LJ, Baxter MK, Plafker SM, Gibson W: Human cytomegalovirus capsid assembly protein precursor (pUL80.5) interacts with itself and with the major capsid protein (pUL86) through two different domains. J Virol 1997, 71:179-190.
14. Matusick-Kumar L, Hurlburt W, Weinheimer SP, Newcomb WW, Brown JC, Gao M: Phenotype of the herpes simplex virus type 1 protease substrate ICP35 mutant virus. J Virol 1994, 68:5384-5394.
15. Matusick-Kumar L, Newcomb WW, Brown JC, McCann PJ III, Hurlburt W, Weinheimer SP, Gao M: The C-terminal 25 amino acids of the protease and its substrate ICP35 of herpes simplex virus type 1 are involved in the formation of sealed capsids. J Virol 1995, 69:4347-4356.
16. Haanes EJ, Thomsen DR, Martin S, Homa FL, Lowery DE: The bovine herpesvirus 1 maturational proteinase and scaffold proteins can substitute for the homologous herpes simplex virus type 1 proteins in the formation of hybrid type B capsids. J Virol 1995, 69:7375-7379.
17. Oien NL, Thomsen DR, Wathen MW, Newcomb WW, Brown JC, Homa FL: Assembly of herpes simplex virus capsids using the human cytomegalovirus scaffold protein: critical role of the C terminus. J Virol 1997, 71:1281-1291.
18. Robertson BJ, McCann PH III, Matusick-Kumar L, Newcomb WW, Brown JC, Colonno RJ, Gao M: Separate functional domains of the herpes simplex virus type 1 protease: evidence for cleavage inside capsids. J Virol 1996, 70:4317-4328.
19. Welch AR, McNally LM, Hall MR, Gibson W: Herpesvirus proteinase: site-directed mutagenesis used to study maturational, release, and inactivation cleavage sites of precursor and to identify a possible catalytic site serine and histidine. J Virol 1993, 67:7360-7372.
20. Dilanni CL, Drier DA, Deckman IC, McCann PJ III, Liu F, Roizman B, Colonno RJ, Cordingley MG: Identification of the herpes simplex virus-1 protease cleavage sites by direct sequence analysis of autoproteolytic cleavage products. J Biol Chem 1993, 268:2048-2051.
21. Holwerda BC, Wittwer AJ, Duffin KL, Smith C, Toth MV, Carr LS, Wiegand RC, Bryant ML: Activity of two-chain recombinant human cytomegalovirus protease. J Biol Chem 1994, 269:25911-25915.
22. Stevens JT, Mapelli C, Tsao J, Hail M, O'Boyle DR II, Weinheimer SP, Dilanni CL: In vitro proteolytic activity and active-site identification of the human cytomegalovirus protease. Eur J Biochem 1994, 226:361-367.
23. Cox GA, Wakulchik M, Sassmannshausen LM, Gibson W, Villarreal EC: Human cytomegalovirus proteinase: candidate glutamic acid identified as third member of putative active-site triad. J Virol 1995, 69:4524-4528.
24. ••].
25. ••].
26. ••].
27. ••] are seminal papers which have been recently published and which describe the novel structure of the HCMV protease.
28. Liu F, Roizman B: Characterization of the protease and other products of amino-terminus-proximal cleavage of the herpes simplex virus 1 UL26 protein. J Virol 1993, 67:1300-1309.
29. Weinheimer SP, McCann PJ III, O'Boyle DR II, Stevens JT, Boyd BA, Drier DA, Yamanaka GA, Dilanni CL, Deckman IC, Cordingley MG: Autoproteolysis of herpes simplex virus type 1 protease releases an active catalytic domain found in intermediate capsid particles. J Virol 1993, 67:5813-5822.
30. Baum EZ, Bebernitz GA, Hulmes JD, Muzithras VP, Jones TR, Gluzman Y: Expression and analysis of the human cytomegalovirus UL80 encoded protease: identification of autoproteolytic sites. J Virol 1993, 67:497-506.
31. Jones TR, Sun L, Bebernitz GA, Muzithras VP, Kim HJ, Johnston SH, Baum EZ: Proteolytic activity of human cytomegalovirus UL80 protease cleavage site mutants. J Virol 1994, 68:3742-3752.
32. Welch AR, Villarreal EC, Gibson W: Cytomegalovirus protein substrates are not cleaved by the herpes simplex virus type 1 proteinase. J Virol 1995, 69:341-347.
33. Godefroy S, Guenet C: Autoprocessing of hsv-1 protease: Effect of deletions on autoproteolysis. FEBS Lett 1995, 357:168-172.
34. McCann PJI, O'Boyle DR II, Deckman IC: Investigation of the specificity of the herpes simplex virus type 1 protease by point mutagenesis of the autoproteolysis sites. J Virol 1994, 68:526-529.
35. Burck PJ, Berg DH, Luk TP, Sassmannshausen LM, Wakulchik M, Smith DP, Hsiung HM, Becker GW, Gibson W, Villarreal EC: Human cytomegalovirus maturational proteinase: expression in Escherichia coli, purification, and enzymatic characterization by using peptide substrate mimics of natural cleavage sites. J Virol 1994, 68:2937-2946.
36. Donaghy G, Jupp R: Characterization of the Epstein-Barr virus proteinase and comparison with the human cytomegalovirus proteinase. J Virol 1995, 69:1265-1270.
37. Dilanni CL, Mapelli C, Drier DA, Tsao J, Natarajan S, Riexinger D, Festin SM, Bolgar M, Yamanaka G, Weinheimer SP, et al.: In vitro activity of the herpes simplex virus type 1 protease with peptide substrates. J Biol Chem 1993, 268:25449-25454.
38. Darke PL, Chen E, Hall DL, Sardana MK, Veloski CA, LaFemina RL, Shafer JA, Kuo LC: Purification of active herpes simplex virus-1 protease expressed in Escherichia coli. J Biol Chem 1994, 269:18708-18711.
39. Sardana VV, Wolfgang JA, Veloski CA, Long WJ, LeGrow K, Wolanski B, Emini EA, LaFemina RL: Peptide substrate cleavage specificity of the human cytomegalovirus protease. J Biol Chem 1994, 269:14337-14340.
40. LaFemina RL, Bakshi K, Long WL, Pramanik B, Veloski CA, Wolanski BS, Marcy Al, Hazuda DJ: Characterization of a soluble stable human cytomegalovirus protease and inhibition by M-site peptide mimics. J Virol 1996, 70:4819-4824.
41. Smith MC, Giordano J, Cook JA, Wakulchik M, Villarreal EC, Becker GW, Bemis K, Labus J, Manetta JS: Purification and kinetic characterization of human cytomegalovirus protease. Meth Enzymol 1994, 244:412-423.
42. Pinko C, Margosiak SA, Vanderpool D, Gutowski JC, Condon B, Kan CC: Single-chain recombinant human cytomegalovirus protease: activity against its natural protein substrate and fluorogenic peptide substrates. J Biol Chem 1995, 270:23634-23640.
43. Handa BK, Keech E, Conway EA, Broadhurst A, Ritchie A: Design and synthesis of a quenched fluorogenic peptide substrate for human cytomegalovirus proteinase. Antiviral Chem Chemother 1995, 6:255-261.
44. Holskin BP, Bukhtiyarova M, Dunn BM, Baur P, DeChastonay J, Pennington MW: A continuous fluorescence-based assay of human cytomegalovirus protease using a peptide substrate. Anal Biochem 1995, 227:148-155.
45. Tigue NJ, Matharu PJ, Roberts NA, Mills JS, Kay J, Jupp R: Cloning, expression, and characterization of the proteinase from human herpesvirus-6. J Virol 1996, 70:4136-4141.
46. 33phosphorous. Anal Biochem 1996, 237:129-134. This paper describes a high-throughput HCMV assay for HCMV protease activity based on scintillation proximity technology.
47. Levine LM, Michener M, Toth MV, Holwerda BC: Measurement of specific protease activity utilizing fluorescence polarization. Anal Biochem 1997, 247:83-88. This paper describes the use of substrate fluoresence polarization as a useful technology for application in high-throughput screening.
48. Hall DL, Darke PL: Activation of the herpes simplex virus type 1 protease. J Biol Chem 1995, 270:22697-22700.
49. O'Boyle DRI, Wager-Smith K, Stevens KT III, Weinheimer SP: The effect of internal autocleavage on kinetic properties of the human cytomegalovirus protease catalytic domain. J Biol Chem 1995, 270:4753-4758.
50. Margosiak SA, Vanderpool DL, Sisson W, Pinko C, Kan CC: Dimerization of the human cytomegalovirus protease: kinetic and biochemical characterization of the catalytic homodimer. Biochemistry 1996, 35:5300-5307.
51. Darke PL, Cole JL, Waxman L, Hall DL, Sardana MK, Kuo LC: Active human cytomegalovirus protease is a dimer. J Biol Chem 1996, 271:7445-7449.
52. Cole JL: Characterization of human cytomegalovirus protease dimerization by analytical centrifugation. Biochemistry 1996, 35:15601-15610.
53. Yamanaka G, Dilanni CL, O'Boyle DR II, Stevens J, Weinheimer SP, Deckman IC, Matusick-Kumar L, Colonno RJ: Stimulation of the herpes simplex virus type I protease by antichaeotrophic salts. J Biol Chem 1995, 270:30168-30172.
54. Knight WB, Green BG, Chabin RM, Maycock AL, Weston H, Kuo DW, Westler WM, Dorn CP, Finke PE, Hagmann WK et al.: Specificity, stability, and potency of moncyclic β-lactam inhibitors of human leukocyte elastase. Biochemistry 1992, 31:8160-8170.
55. Hlasta DJ, Bell MR, Boaz NW, Court JJ, Desai RC, Franke CA, Mura AJ, Subramanyam C, Dunlap RP: A benzisothiazolone class of potent, selective mechanism-based inhibitors of human leukocyte elastase. Bioorg Med Chem Lett 1994, 4:1801-1806.
56. Stein RL, Strimpler AM, Viscarello BR, Wildonger RA, Mauger RC, Trainor DA: Mechanism for slow-binding inhibition of human leukocyte elastase by valine-dervied benzoxazinones. Biochemistry 1987, 26:4126-4130.
57. ••].
58. ••] are the first disclosed reports of alternate substrate inhibitors of the herpesvirus proteases.
59. Flynn DL, Becker DP, Hippenmeyer P, Hockerman S, Houseman K, Moormann A, Rankin A, Williams K, Wittwer A, Zablocki J et al.: Selective inhibitors of herpesvirus serine protease assemblin. Abstract 241 of the 211th American Chemical Society National Meeting, 1996 March 24-28, New Orleans.
60. Hippenmeyer PJ, Dilworth VM: A rapid assay for determination of antiviral activity against human cytomegalovirus. Antiviral Res 1996, 32:35-42.
61. Flynn DL, Becker DP, Dilworth VM, Highkin MK, Hippenmeyer PJ, Houseman KA, Levine LM, Li M, Moormann AE, Rankin A et al.: The herpesvirus protease: mechanistic studies and discovery of inhibitors of the human cytomegalovirus protease. Drug Des Discov 1997, 15:3-15. This reference describes a novel fluorogenic substrate assay (DABCYLEDANS substrate) and also describes the essential role of reduced cysteine residues for HCMV protease activity. The thiol-modifying class of benzimidazolylmethyl sulfoxides is also disclosed in this paper.
62. Baum EZ, Siegel MM, Bebernitz GA, Hu TR, Gluzman Y: Inhibition of human cytomegalovirus UL80 protease by specific intramolecular disulfide formation. Biochemistry 1996, 35:5838-5846. This is one of the first references describing the inhibition of HCMV protease via a thiol-modifying mechanism.
63. Lindberg P, Brandstrom A, Wallmark B: Structure-activity relationships of omeprazole analogues and their mechanism of action. Trends Pharmacol Sci 1987, 8:399-402.
64. Baum EZ, Ding WD, Siegel MM, Hulmes J, Bebernitz GA, Sridharan L, Tabei K, Krishnamurthy G, Carofiglio T, Groves JT et al.: Flavins inhibit cytomegalovirus UL80 protease via disulfide bond formation. Biochemistry 1996, 35:5847-5855. This is one of the first references to describe the inhibition of HCMV protease via a thiol-modifying mechanism.